Xiang L. Yan

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications

Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report.

Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report.

Journal: Clinical case reports
Published: December 25, 2025

Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.

Adjuvant chemotherapy for completely resected stage IB-IIA non-small cell lung cancer according to the AJCC 8th edition staging system: a real-world retrospective cohort study based on the SEER database.

Journal: Translational lung cancer research
Published: December 06, 2025

Multiomics elucidation of surrounding AT2 cells impeding tertiary lymphoid structures function in neoadjuvant chemoimmunotherapy response of multiple primary lung cancers.

Multiomics elucidation of surrounding AT2 cells impeding tertiary lymphoid structures function in neoadjuvant chemoimmunotherapy response of multiple primary lung cancers.

Journal: Journal for immunotherapy of cancer
Published: September 10, 2025

Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort study.

Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort study.

Journal: Translational lung cancer research
Published: August 20, 2025

Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.

Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 20, 2025

Effect of neoadjuvant vs. adjuvant systemic therapy on survival in patients with surgical resected limited stage small-cell lung cancer: a real-world retrospective cohort study from SEER database.

Effect of neoadjuvant vs. adjuvant systemic therapy on survival in patients with surgical resected limited stage small-cell lung cancer: a real-world retrospective cohort study from SEER database.

Journal: Translational lung cancer research
Published: April 17, 2025

Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation.

Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation.

Journal: NPJ precision oncology
Published: March 31, 2025

Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial.

Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial.

Journal: BMC medicine
Published: March 19, 2025

Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.

Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.

Journal: BMC cancer
Published: March 07, 2025

Mast cell leukemia: a rare case report and literature review.

Mast cell leukemia: a rare case report and literature review.

Journal: Frontiers in oncology
Published: November 30, 2024

Potential Value of Neoadjuvant Immunochemotherapy in Patients 
with Driver Gene-positive Non-small Cell Lung Cancer

Potential Value of Neoadjuvant Immunochemotherapy in Patients 
with Driver Gene-positive Non-small Cell Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: November 04, 2024

Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome.

Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome.

Journal: Journal of pharmaceutical and biomedical analysis
Published: October 24, 2024
Showing 1-12 of 77

Last Updated: 09/26/2026